News releases and announcements

06 August 2008	Interim Results for the Six Months Ended 30 June 2008
06 August 2008	Drug R&D Division New employee share option scheme in Hutchison MediPharma
18 July 2008	Notice of 2008 Interim Results
30 June 2008	Blocklisting Six Monthly Return
10 June 2008	Director's Shareholding
02 June 2008	Board Change
23 May 2008	China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture
19 May 2008	Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores
09 May 2008	Results of Annual General Meeting
22 April 2008	Holding in Company
09 April 2008	Annual Report 2007 and Notice of Annual General Meeting
31 March 2008	Holding in Company
19 March 2008	Preliminary Results for the year ended 31 December 2007
29 February 2008	Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate
28 February 2008	Change in the Registered Office Address in the Cayman Islands
28 February 2008	Notice of 2007 Preliminary Results
21 January 2008	Strong growth in China Healthcare division Streamlining of product range set to further improve financial performance
27 December 2007	Block Admission Return
05 December 2007	Chi-Med has been shortlisted 2007 Scrip Award for Best Company in an Emerging Market
22 November 2007	Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients
20 August 2007	Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company
09 August 2007	Interim Results for the Six Months Ended 30 June 2007
18 July 2007	Notice of Interim Results
02 July 2007	Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
22 June 2007	Block Admission
18 June 2007	Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility
23 May 2007	Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China
22 May 2007	Director's Shareholding
11 May 2007	Results of Annual General Meeting
12 April 2007	Annual Report and Accounts 2006 - Notice of Annual General Meeting
02 April 2007	Board Change
23 March 2007	Director's Shareholding
21 March 2007	Preliminary Results for the year ended 31 December 2006
26 February 2007	Notice of Preliminary Results
17 January 2007	Related party transaction Chi-Med formalises China Sales and Distribution Arrangements
05 January 2007	Appointment of Joint Broker
20 November 2006	Chi-Med and Merck KGaA Start Collaboration to Discover Novel Small Molecule Anti-Cancer Drugs
06 November 2006	Development Agreement with Procter & Gamble for the Discovery and Development of New Active Ingredients for Beauty Products
29 September 2006	Appointment of Senior Independent Director
09 August 2006	Financial Results for the Six Months Ended 30 June 2006
26 July 2006	Notice of Maiden Interim Results
17 July 2006	Trading Update
04 July 2006	Chi-Med plans to broaden clinical trials of its leading oncology drug candidate